This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-26. Anything still debated is marked as such rather than presented as settled.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid, appearance varies by batch |
| Solubility | Soluble in water | Also dissolves in aqueous buffer; side chain alters behavior |
| Storage, dry powder | Minus 20 degrees Celsius or below | Desiccated and protected from light |
| Storage, in solution | 2 to 8 degrees Celsius | Short term only; avoid repeated freeze-thaw |
| Primary assay | Reversed-phase HPLC | Frequently paired with mass spectrometry |
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
In information technology, a backup, or data backup is a copy of computer data taken and stored elsewhere so that it may be used to restore the original after a data loss event. The verb form, referring to the process of doing so, is "back up", whereas the noun and adjective form is "backup". Backups can be used to recover data after its loss from data deletion or corruption, or to recover data from an earlier time. Backups provide a simple form of IT disaster recovery; however not all backup systems are able to reconstitute a computer system or other complex configuration such as a computer cluster, active directory server, or database server. A backup system contains at least one copy of all data considered worth saving. The data storage requirements can be large. An information repository model may be used to provide structure to this storage. There are different types of data storage devices used for copying backups of data that is already in secondary storage onto archive files. There are also different ways these devices can be arranged to provide geographic dispersion, data security, and portability. Data is selected, extracted, and manipulated for storage. The process can include methods for dealing with live data, including open files, as well as compression, encryption, and de-duplication. Additional techniques apply to enterprise client-server backup. Backup schemes may include dry runs that validate the reliability of the data being backed up. There are limitations and human factors involved in any backup scheme.
=== Thermal management === In 2011, researchers reported that a three-dimensional, vertically aligned, functionalized multilayer graphene architecture can be an approach for graphene-based thermal interfacial materials (TIMs) with superior thermal conductivity and ultra-low interfacial thermal resistance between graphene and metal. Graphene-metal composites can be used in thermal interface materials. Adding a layer of graphene to each side of a copper film increased the metal's heat-conducting properties up to 24%. This suggests the possibility of using them for semiconductor interconnects in computer chips. The improvement is the result of changes in copper's nano- and microstructure, not from graphene's independent action as an added heat conducting channel. High temperature chemical vapor deposition stimulates grain size growth in copper films. The larger grain sizes improve heat conduction. The heat conduction improvement was more pronounced in thinner copper films, which is useful as copper interconnects shrink. Attaching graphene functionalized with silane molecules increases its thermal conductivity (κ) by 15–56% with respect to the number density of molecules. This is because of enhanced in-plane heat conduction resulting from the simultaneous increase of thermal resistance between the graphene and the substrate, which limited cross-plane phonon scattering. Heat spreading ability doubled. However, mismatches at the boundary between horizontally adjacent crystals reduces heat transfer by a factor of 10.
=== Receptor activation === The initial triggering follows the mechanism common for all NTR receptor family members. Once the TCR binds a specific pMHC, the tyrosine residues of the immunoreceptor tyrosine-based activation motifs (ITAMs) in its CD3 adaptor proteins are phosphorylated. The residues serve as docking sites for downstream signaling molecules, which can propagate the signal. Phosphorylation of ITAMs is mediated by the Src kinase Lck. Lck is anchored to the plasma membrane by associating with the co-receptor CD4 or CD8, depending on the T-cell subtype. CD4 is expressed on helper T cells and regulatory T cells, and is specific for MHC class II. CD8, on the other hand, specific for MHC class I, is expressed on cytotoxic T cells. Binding of the co-receptor to the MHC brings Lck in close proximity to the CD3 ITAMs. It has been shown that 40% of Lck is active even before the TCR binds pMHC and therefore has the ability to constantly phosphorylate the TCR. Tonic TCR signaling is avoided by the presence of phosphatase CD45 that removes phosphorylation from tyrosine residues and inhibits signal initiation. Upon binding the balance of kinase activity to phosphatase activity is perturbed, leading to a surplus of phosphorylation and initiation of the signal. How such perturbation is accomplished by TCR binding is still debated. Mechanisms involving conformational change of TCR, TCR aggregation and kinetic segregation have been suggested. Tyrosine kinase Fyn might be involved in ITAM phosphorylation but is not essential for TCR signaling.
== Paralogy == Paralogous genes are genes that are related via duplication events in the last common ancestor (LCA) of the species being compared. They result from the mutation of duplicated genes during separate speciation events. When descendants from the LCA share mutated homologs of the original duplicated genes then those genes are considered paralogs. As an example, in the LCA, one gene (gene A) may get duplicated to make a separate similar gene (gene B), those two genes will continue to get passed to subsequent generations. During speciation, one environment will favor a mutation in gene A (gene A1), producing a new species with genes A1 and B. Then in a separate speciation event, one environment will favor a mutation in gene B (gene B1) giving rise to a new species with genes A and B1. The descendants' genes A1 and B1 are paralogous to each other because they are homologs that are related via a duplication event in the last common ancestor of the two species. Additional classifications of paralogs include alloparalogs (out-paralogs) and symparalogs (in-paralogs). Alloparalogs are paralogs that evolved from gene duplications that preceded the given speciation event. In other words, alloparalogs are paralogs that evolved from duplication events that happened in the LCA of the organisms being compared. The example above is an example alloparalogy. Symparalogs are paralogs that evolved from gene duplication of paralogous genes in subsequent speciation events.
This test can't determine the precise distance of gun to target, however, it is often used around holes to determine if it is consistent with the passage of a bullet. The Harrison and Gilroy method was introduced in 1959. It is a colorimetric test used to verify the presence of antimony, lead and/or barium. The test involves dampening a cloth with 0.1M hydrochloric acid (HCl), swabbing the item being analysed and allowing that to dry before subjecting it to various reagents. The sensitivities of the reagents used makes this test very unreliable and unrealistic for crime scene analysis.
Sources: en.wikipedia.org
==== Books ==== In the 1942 short story "Funes the Memorious" by Jorge Luis Borges, the protagonist suffers a head injury after which he gains the ability to remember every detail of what he experiences, but comes to view this as a curse. In the 1980 series The Book of the New Sun by Gene Wolfe, the protagonist remembers everything he has ever seen starting from infancy. He describes his memories as being so vivid that he is capable of re-living anything he has experienced whenever he chooses to do so. In a 2011 manga by Kohske called Gangsta, the main character, Worick Arcangelo, is said to have hyperthymesia, which he uses to help police identify murder victims. In the 2015 novel Memory Man by David Baldacci, the protagonist, Amos Decker, has hyperthymesia. In the book, a mystery-crime scene-thriller with graphic scenes, Decker uses his perfect memory brought on by a traumatic hit in football to solve the murder of his wife and child, and the school shooting connected to it. Decker recalls his memories as a "DVR", just playing when it wants to, or being rewound and played forward by conscious thought. In the 2021 romantic suspense series Memento Mori by C.S. Poe, the protagonist, Everett Larkin, has hyperthymesia. Larkin suffered a traumatic brain injury at the age of 18, leaving him with highly superior autobiographical memory (HSAM) but very poor short-term memory. He remembers events since his injury with perfect recall, and memories are often brought to the surface through "associations." Larkin uses his superior memory as a detective on the NYPD cold case squad.
==== 1700–1799 ==== A249 Trunk Road (Brielle Way/Docks Entrance) Order 1993 (S.I. 1993/1700) Craigie College of Education (Closure) (Scotland) Order 1993 (S.I. 1993/1701) Supply of Razors and Razor Blades (Interim Provision) (Revocation) Order 1993 (S.I. 1993/1702) Merger Situation (Stora/Swedish Match/Gillette) (Interim Provision) (Revocation) Order 1993 (S.I. 1993/1703) Land Registration (Charities) Rules 1993 (S.I. 1993/1704) A65 Trunk Road (Gargrave Bypass) Order 1990 Amendment and New Trunk Road Order 1993 (S.I. 1993/1705) A65 Trunk Road (Horse Pasture Laithe to Heber Barn) (Detrunking) Order 1993 (S.I. 1993/1706) Removal and Disposal of Vehicles(Amendment) (No. 3) Regulations 1993 (S.I. 1993/1708) Inshore Fishing (Prohibition of Fishing for Cockles) (Scotland) Order 1993 (S.I. 1993/1709) Motor Vehicles (Designation of Approval Marks) (Amendment) Regulations 1993 (S.I. 1993/1710) Plant Breeders' Rights (Trees, Shrubs and Woody Climbers) (Variation) Scheme 1993 (S.I. 1993/1733) Beef Special Premium Regulations 1993 (S.I. 1993/1734) Reconstitution of the Upper Witham Internal Drainage Board Order 1993 (S.I. 1993/1738) Social Security (Introduction of Disability Living Allowance) (Amendment) (No.2) Regulations 1993 (S.I. 1993/1739) Kent and East Sussex (County Boundaries) Order 1993 (S.I. 1993/1742) Coal Industry (Restructuring Grants) Order 1993 (S.I. 1993/1745) Chemicals (Hazard Information and Packaging) Regulations 1993 (S.I. 1993/1746) A35 Trunk Road (Tolpuddle to Puddletown Bypass and Slip Roads) Order 1993 (S.I.
Vitamin K: CID 5280483 from PubChem Vitamin K1 (phylloquinone, phytomenadione): CID 5284607 from PubChem Vitamin K2 (menaquinone 6): CID 5283547 from PubChem Vitamin K3 (menadione): CID 4055 from PubChem
The racial makeup of Raleigh in 2023 was 52.5% non-Hispanic White, 28.1% Black or African American, 0.3% American Indian or Alaska Native, 4.5% Asian American, 0.1% from some other race, 6.9% two or more races, 11.6% Hispanic or Latin American of any race. According to the 2010 United States census, the racial composition of the city was: 57.5% White (53.3% non-Hispanic White), 29.3% Black or African American, 4.3% Asian American (1.2% Indian, 0.8% Chinese, 0.7% Vietnamese, 0.5% Korean, 0.4% Filipino, 0.1% Japanese), 2.6% two or more races, 1.4% some other race, 0.5% Native American, and <0.1% Native Hawaiian or other Pacific Islander In addition, 11.4% of city residents were Hispanic or Latino Americans, of any race (5.9% Mexican, 1.1% Puerto Rican, 0.9% Salvadoran, 0.6% Dominican, 0.6% Honduran, 0.3% Colombian, 0.3% Cuban, 0.2% Guatemalan, 0.2% Spanish, 0.2% Peruvian, 0.1% Venezuelan, 0.1% Ecuadorian, 0.1% Argentine, and 0.1% Panamanian). In 2000, the racial composition of the city was: 63.31% White, 27.80% Black or African American, 7.01% Hispanic or Latino American, 3.38% Asian American, 0.36% Native American, 0.04% Native Hawaiian or other Pacific Islander, 3.24% some other race, and 1.88% two or more races.
==== MeSH D06.472.420 – hypothalamic hormones ==== MeSH D06.472.420.349 – pituitary adenylate cyclase-activating polypeptide MeSH D06.472.420.700 – pituitary hormone release inhibiting hormones MeSH D06.472.420.700.500 – msh release-inhibiting hormone MeSH D06.472.420.700.750 – prolactin release-inhibiting hormone MeSH D06.472.420.700.875 – somatostatin MeSH D06.472.420.740 – pituitary hormone-releasing hormones MeSH D06.472.420.740.140 – corticotropin-releasing hormone MeSH D06.472.420.740.320 – gonadorelin MeSH D06.472.420.740.320.100 – buserelin MeSH D06.472.420.740.320.340 – goserelin MeSH D06.472.420.740.320.400 – leuprolide MeSH D06.472.420.740.320.580 – nafarelin MeSH D06.472.420.740.320.790 – triptorelin MeSH D06.472.420.740.530 – msh-releasing hormone MeSH D06.472.420.740.720 – prolactin-releasing hormone MeSH D06.472.420.740.860 – somatotropin-releasing hormone MeSH D06.472.420.740.860.780 – sermorelin MeSH D06.472.420.740.880 – thyrotropin-releasing hormone
Sources: en.wikipedia.org
Reversed-phase liquid chromatography with ultraviolet detection is the standard approach, reported as area percent of the main peak. Orthogonal methods such as mass spectrometry confirm that the main peak has the expected mass. Purity figures are only comparable when column, gradient, and wavelength are matched.
Dry powder is usually kept at minus 20 degrees Celsius or below in a sealed, desiccated container. Once dissolved, material is refrigerated and used quickly. These conventions apply to research-grade peptides generally, not to a specific marketed product.
Chromatography separates components but does not confirm what they are. Mass spectrometry assigns a mass to each peak, which identifies the target peptide and flags modifications such as oxidation or truncation. The two techniques together give both a quantity and an identity check.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.